+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oncology Biosimilars Market - Global Forecast 2026-2032- Product Image
Oncology Biosimilars Market - Global Forecast 2026-2032- Product Image
New

Oncology Biosimilars Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 192 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968765
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The oncology biosimilars market is entering a pivotal phase, with innovation and regulatory alignment shaping how cancer therapies are accessed and delivered globally. Senior decision-makers require a clear view of commercial pathways, operational challenges, and emerging practices to ensure long-term organizational advantage in this competitive space.

Market Snapshot: Oncology Biosimilars Market Size and Growth

In 2025, the global oncology biosimilars market reached USD 7.79 billion, with expectations to grow to USD 8.66 billion in 2026, reflecting a compound annual growth rate (CAGR) of 13.04%. Looking ahead to 2032, the market is projected to achieve USD 18.38 billion. This robust growth trajectory is driven by healthcare systems’ efforts to expand patient access and manage drug costs more effectively compared to originator biologics. Major growth factors include rising adoption of value-based care, new biosimilar entries expanding therapeutic choices, and positioning to meet evolving regional regulatory requirements.

Scope & Segmentation of the Oncology Biosimilars Market

  • Product Types: Includes biosimilars for leading reference biologics such as bevacizumab, cetuximab, rituximab, and trastuzumab, along with those in the pipeline innovating administration methods. Monitoring these developments supports informed portfolio management and enables better anticipation of market competition.
  • Therapeutic Indications: Encompasses applications in breast, colorectal, lung, gastric, and hematologic cancers. Segment analysis reveals shifting clinical demand and payer preferences, guiding targeted strategies across key cancer types.
  • Administration Routes: Assesses both established intravenous and emerging subcutaneous delivery models, in addition to co-formulation advancements. Understanding these can help organizations adapt to the trend toward outpatient treatment and enhanced patient convenience.
  • Distribution Channels: Covers hospital, specialty, retail, and online pharmacies. Segment intelligence allows decision-makers to optimize supply chain efficiency and cost by tracking procurement cycles and digital platform adoption.
  • Geographic Regions: Focuses on North America, Europe, Asia-Pacific, the Middle East, and Africa. Evaluating regional market structures, regulatory harmonization, and payer dynamics supports tailored scenario planning and risk reduction initiatives.
  • Technology Trends: Highlights advances in single-use manufacturing systems and flexible bioproduction. Emphasizing supply chain resilience, these advancements support localized production and agile responsiveness to fluctuating market needs.

Oncology Biosimilars Market: Key Takeaways for Decision-Makers

  • Clearer regulatory frameworks and increased real-world evidence contribute to faster clinical adoption, while also supporting payer and clinician confidence in biosimilars.
  • Shifts in administration practices, for example subcutaneous delivery, are enabling the transition from traditional inpatient to outpatient cancer care, prompting a reassessment of hospital resource planning and throughput.
  • Growing complexity in stakeholder decision-making arises as policies on interchangeability and tendering strategies require careful alignment of pricing, supply consistency, and operational priorities.
  • Collaborative manufacturing arrangements and scalable, single-use production technologies are important for improving local market access and rapid adaptation to regional disruptions.
  • Evolving contracting frameworks now integrate value-based and indication-specific elements to better address payer demands and support more precise clinical and economic objectives.
  • Integrated support programs and advances in digital patient engagement differentiate leading manufacturers by promoting patient adherence and operational efficiency throughout the biosimilars lifecycle.

Tariff Impact: Navigating Trade Policy and Supply Chain Resilience

Recent U.S. tariff actions are adding new complexities to the oncology biosimilars supply chain. These measures are driving shifts in input costs and prompting reevaluation of logistics and inventory management. As manufacturers respond, investment increasingly favors nearshoring, with regionalized production supporting faster adaptation to disruptions. Organizations with extensive cross-border dependencies face heightened procurement and contracting uncertainties, emphasizing the importance of robust risk mitigation and versatile sourcing models.

Methodology & Data Sources

This analysis draws from interviews with experts across clinical practice, procurement, payer leadership, and executive roles. Comprehensive review of regulatory documents, clinical publications, and manufacturing advances is complemented by scenario modeling and supply chain risk assessment, ensuring actionable insights that align with current realities and future uncertainties in the oncology biosimilars market.

Why This Report Matters: Actionable Guidance for Leadership

  • Shape resilient portfolio and procurement strategies by anticipating the impact of regulatory and market developments unique to oncology biosimilars.
  • Enable senior leaders, procurement teams, and clinicians to invest confidently in technology, distribution, and service delivery innovations that drive organizational value.
  • Strengthen scenario planning and supply chain continuity, supporting stable biosimilar access in an increasingly complex policy and tariff environment.

Conclusion

Success in the oncology biosimilars market relies on adaptability and well-informed, collaborative strategies. Organizations that align stakeholder goals and leverage proven frameworks are positioned to expand access and realize long-term value.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Oncology Biosimilars Market, by Product Type
8.1. Bevacizumab
8.2. Cetuximab
8.3. Rituximab
8.4. Trastuzumab
9. Oncology Biosimilars Market, by Therapeutic Indication
9.1. Breast Cancer
9.2. Colorectal Cancer
9.3. Gastric Cancer
9.4. Lung Cancer
9.5. Non-Hodgkin's Lymphoma
10. Oncology Biosimilars Market, by Route Of Administration
10.1. Intravenous Infusion
10.2. Subcutaneous Injection
11. Oncology Biosimilars Market, by Distribution Channel
11.1. Hospital Pharmacies
11.2. Online Pharmacies
11.3. Retail Pharmacies
11.4. Specialty Pharmacies
12. Oncology Biosimilars Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Oncology Biosimilars Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Oncology Biosimilars Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Oncology Biosimilars Market
16. China Oncology Biosimilars Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Amgen Inc.
17.6. Biocon Limited
17.7. Celltrion, Inc.
17.8. Dr. Reddy's Laboratories Limited
17.9. Eli Lilly and Company
17.10. Fresenius Kabi AG
17.11. Pfizer Inc.
17.12. Samsung Bioepis Co., Ltd.
17.13. Sandoz AG
17.14. Teva Pharmaceutical Industries Ltd.
17.15. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ONCOLOGY BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ONCOLOGY BIOSIMILARS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY CETUXIMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY CETUXIMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY CETUXIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY RITUXIMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY RITUXIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY TRASTUZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY TRASTUZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY TRASTUZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY GASTRIC CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY GASTRIC CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY GASTRIC CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY NON-HODGKIN'S LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY NON-HODGKIN'S LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY NON-HODGKIN'S LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY INTRAVENOUS INFUSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY INTRAVENOUS INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 53. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 54. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
TABLE 55. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 56. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 57. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 59. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
TABLE 60. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 61. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 62. LATIN AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. LATIN AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 64. LATIN AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
TABLE 65. LATIN AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 66. LATIN AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 67. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 68. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 69. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
TABLE 70. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 71. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 72. EUROPE ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. EUROPE ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 74. EUROPE ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
TABLE 75. EUROPE ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 76. EUROPE ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 77. MIDDLE EAST ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. MIDDLE EAST ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 79. MIDDLE EAST ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
TABLE 80. MIDDLE EAST ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 81. MIDDLE EAST ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 82. AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 84. AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
TABLE 85. AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 86. AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. ASEAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. ASEAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 95. ASEAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
TABLE 96. ASEAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 97. ASEAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 98. GCC ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GCC ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 100. GCC ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
TABLE 101. GCC ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 102. GCC ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 103. EUROPEAN UNION ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. EUROPEAN UNION ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 105. EUROPEAN UNION ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
TABLE 106. EUROPEAN UNION ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 107. EUROPEAN UNION ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 108. BRICS ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. BRICS ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 110. BRICS ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
TABLE 111. BRICS ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 112. BRICS ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 113. G7 ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. G7 ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 115. G7 ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
TABLE 116. G7 ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 117. G7 ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 118. NATO ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 119. NATO ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 120. NATO ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
TABLE 121. NATO ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 122. NATO ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 125. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 126. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
TABLE 127. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 128. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 129. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 130. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 131. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
TABLE 132. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 133. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Oncology Biosimilars market report include:
  • Amgen Inc.
  • Biocon Limited
  • Celltrion, Inc.
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly and Company
  • Fresenius Kabi AG
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sandoz AG
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages192
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 8.66 Billion
Forecasted Market Value ( USD ) by 2032 $ 18.38 Billion
Compound Annual Growth Rate13.0%
Regions CoveredGlobal
No. of Companies Mentioned12

Related Topics

Related Reports

Biosimilar Monoclonal Antibodies Market - Global Forecast 2026-2032 - Product Image

Biosimilar Monoclonal Antibodies Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Biosimilars Market - Global Forecast 2026-2032 - Product Image

Biosimilars Market - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From
Oncology Biosimilars Market - Product Image

Oncology Biosimilars Market

  • Report
  • 173 Pages
  • Global
From
Trastuzumab Biosimilars Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Trastuzumab Biosimilars Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Oncology Biosimilars Market Report by Drug Type, and Region 2025-2033 - Product Image

Oncology Biosimilars Market Report by Drug Type, and Region 2025-2033

  • Report
  • 140 Pages
  • Global
From

About the Oncology Biosimilars Market

Oncology Biosimilars are biotechnology-based drugs that are designed to replicate the therapeutic effects of existing biologic drugs used to treat cancer. These drugs are developed using advanced biotechnology techniques, such as recombinant DNA technology, to create a molecule that is similar to the original biologic drug. Oncology Biosimilars are intended to provide a cost-effective alternative to the original biologic drug, while still providing the same therapeutic benefits. Oncology Biosimilars are regulated by the FDA and must meet the same safety and efficacy standards as the original biologic drug. The approval process for Oncology Biosimilars is more rigorous than that of generic drugs, as the FDA requires additional clinical trials to demonstrate the safety and efficacy of the drug. Oncology Biosimilars are becoming increasingly popular as a cost-effective alternative to the original biologic drugs. As the cost of biologic drugs continues to rise, Oncology Biosimilars offer a more affordable option for patients. Some companies in the Oncology Biosimilars market include Amgen, Pfizer, Merck, and Novartis. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.